Short, calm briefs on GLP-1 medications and fasting research — what happened, and what it might mean for you. We summarize; the linked sources report.
Intermittent fasting matches calorie counting for weight loss in 18-month trial
An 18-month randomized trial from the University of Adelaide, published in Clinical Nutrition, followed more than 200 adults with obesity and found intermittent fasting produced weight loss similar to daily calorie restriction — both diet groups lost roughly 7 kg at six months, compared with about 2 kg for standard care. Participants said fasting felt less mentally demanding than constant calorie counting. For GLP-1 users building maintenance habits alongside or after medication, it suggests either approach can work — choose the one you can sustain.
Time-restricted eating keeps weight off at one year, early or late window
Researchers at the University of Granada reported in Clinical Nutrition that adults with overweight or obesity who completed a 16:8 time-restricted eating program largely kept the weight off a year later — and both early and late eating windows appeared to work, though early eaters preserved slightly more fat loss. The study was small, at 99 people, but it suggests meal-timing flexibility is reasonable — useful if GLP-1-related appetite changes already shape when you eat.
Medicare's $50-a-month GLP-1 program goes live for eligible beneficiaries
Medicare's GLP-1 Bridge demonstration launched July 1, letting eligible Part D beneficiaries get certain GLP-1 medicines — Wegovy injections and tablets, the Zepbound KwikPen, and Foundayo — for a flat $50 a month through December 2027. Manufacturers supply the drugs at a reduced net price of about $245 a month, and eligibility depends on BMI thresholds plus, in some cases, related health conditions. It appears to be Medicare's first broad coverage of these drugs for weight management, though the $50 copay does not count toward Part D out-of-pocket caps.
FDA moves to keep GLP-1 drugs off the compounding bulks list
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound these drugs from bulk ingredients. Public comments were accepted through June 29, 2026. If finalized, the change would largely close the last broad legal pathway for mass-produced compounded GLP-1s — the agency has linked compounded versions to hundreds of adverse event reports — unless the drugs return to the shortage list. Anyone still using compounded GLP-1s may want to plan a switch to FDA-approved products.
FDA approves orforglipron, the first GLP-1 pill without food or water restrictions
The FDA approved Eli Lilly's orforglipron, brand name Foundayo, for chronic weight management — the first small-molecule GLP-1 pill that can be taken any time of day without food or water restrictions. In the ATTAIN-1 trial, participants lost up to about 12.4% of body weight over 72 weeks, somewhat less than injectables typically show. For people who dislike injections, a once-daily pill with self-pay pricing reported to start around $149 a month could widen access, though insurance coverage will vary.